Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis | Zendy

Kim Papp | Zendy; Kenneth B. Gordon | Zendy; Diamant Thaçi | Zendy; Akimichi Morita | Zendy; Melinda Gooderham | Zendy; Peter Foley | Zendy; Ihab Girgis | Zendy; Sudeep Kundu | Zendy; Subhashis Banerjee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

Author(s) -

Kim Papp,

Kenneth B. Gordon,

Diamant Thaçi,

Akimichi Morita,

Melinda Gooderham,

Peter Foley,

Ihab Girgis,

Sudeep Kundu,

Subhashis Banerjee

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1806382

Subject(s) - placebo , medicine , psoriasis , psoriasis area and severity index , gastroenterology , clinical endpoint , tyrosine kinase 2 , clinical trial , pharmacology , immunology , pathology , receptor , platelet derived growth factor receptor , alternative medicine , growth factor

Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 may be effective in treating psoriasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research